Transcatheter valve repair system market to reach $8.42 billion by 2030

The transcatheter valve repair system market is projected to grow from $5.45 billion in 2025 to $8.42 billion by 2030, driven by rising heart disease, aging populations and broader use of minimally invasive cardiac procedures. North America leads today, while Asia-Pacific is expected to grow fastest.

Why it matters: - The market is tied to the growing need for less invasive heart procedures for patients who may not be good candidates for open-heart surgery. - Rising cases of valvular heart disease and coronary heart disease are expanding demand for transcatheter repair systems. - The outlook signals continued investment opportunities in structural heart technologies, especially mitral valve repair.

What happened: - The Business Research Company published an updated outlook on the transcatheter valve repair system market. - The market is projected to increase from $5.45 billion in 2025 to $5.93 billion in 2026. - The report forecasts the market will reach $8.42 billion by 2030. - The forecast implies a 8.8% CAGR from 2025 to 2026 and a 9.2% CAGR through 2030. - North America was the largest regional market in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample report is available. - The full market report is also available.

The details: - Transcatheter valve repair uses a catheter inserted through a small incision in the leg or chest and guided to the heart with imaging. - The procedure is aimed at patients with severe mitral regurgitation, defined in the release as grade 3+ or higher. - The approach is used when abnormal mitral valve leaflets or surrounding tissue cause the condition and open-heart surgery is too risky. - Growth in the past period was linked to higher prevalence of valvular heart disease, an aging global population, better catheter navigation technology, greater clinician expertise and more specialized cardiac centers. - Future growth is expected to come from wider acceptance of minimally invasive valve repair, stronger demand for transcatheter mitral interventions and expansion of structural heart disease treatment programs. - The report also points to innovation in multi-valve repair technologies, more personalized patient care, broader catheter-based adoption and better device navigation and control. - The report highlights heart disease as a major driver because transcatheter devices can replace defective valves without open surgery. - In March 2024, the Office for Health Improvement and Disparities said about 1,862,500 people in England, or about 3% of the population, were diagnosed with coronary heart disease by general practitioners in the fiscal year ending 2023. - The report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report also includes key technology coverage and future trend analysis.

Between the lines: - The market is shifting from a niche clinical tool toward a broader structural heart treatment category. - The strongest demand appears centered on patients who need effective treatment but face high surgical risk. - Regional leadership suggests established reimbursement and clinical adoption in North America, while Asia-Pacific growth points to rising access and diagnosis rates.

What's next: - The market is expected to keep expanding as minimally invasive repair techniques become more widely accepted. - Adoption should continue to rise for mitral valve repair systems and multi-valve platforms. - Improved device control and navigation will likely remain a key competitive area for developers. - Structural heart treatment programs are expected to broaden across more healthcare systems.

The bottom line: - Transcatheter valve repair is moving from growth phase to scale-up, with demand supported by an aging population, higher heart disease rates and expanding clinical use.